IL132304A0 - Osteoprotegerin binding proteins and receptors - Google Patents

Osteoprotegerin binding proteins and receptors

Info

Publication number: IL132304A0
Authority: IL; Israel
Prior art keywords: fragments; encoding; sequence; nucleic acid; receptors
Prior art date: 1997-04-16

Application number

IL13230498A

Other languages

English (en)

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-16

Filing date

1998-04-15

Publication date

2001-03-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27368158&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL132304(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-16 Priority claimed from US08/842,842 external-priority patent/US5843678A/en

1998-03-30 Priority claimed from US09/052,521 external-priority patent/US6316408B1/en

1998-04-15 Application filed by Amgen Inc filed Critical Amgen Inc

2001-03-19 Publication of IL132304A0 publication Critical patent/IL132304A0/xx

Links

102000014914 Carrier Proteins Human genes 0.000 title abstract 2
108091008324 binding proteins Proteins 0.000 title abstract 2
102000008108 Osteoprotegerin Human genes 0.000 title 1
108010035042 Osteoprotegerin Proteins 0.000 title 1
XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 title 1
102000005962 receptors Human genes 0.000 title 1
108020003175 receptors Proteins 0.000 title 1
239000012634 fragment Substances 0.000 abstract 3
150000007523 nucleic acids Chemical class 0.000 abstract 3
102000039446 nucleic acids Human genes 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
208000020084 Bone disease Diseases 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
210000002997 osteoclast Anatomy 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Steroid Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL13230498A 1997-04-16 1998-04-15 Osteoprotegerin binding proteins and receptors IL132304A0 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US08/842,842 US5843678A (en)	1997-04-16	1997-04-16	Osteoprotegerin binding proteins
US88085597A	1997-06-23	1997-06-23
US09/052,521 US6316408B1 (en)	1997-04-16	1998-03-30	Methods of use for osetoprotegerin binding protein receptors
PCT/US1998/007584 WO1998046751A1 (fr)	1997-04-16	1998-04-15	Proteines de liaison et recepteurs d'osteoprotegerine

Publications (1)

Publication Number	Publication Date
IL132304A0 true IL132304A0 (en)	2001-03-19

Family

ID=27368158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13230498A IL132304A0 (en)	1997-04-16	1998-04-15	Osteoprotegerin binding proteins and receptors

Country Status (28)

Country	Link
US (1)	US7923008B2 (fr)
EP (2)	EP1717315A3 (fr)
JP (2)	JP2001526532A (fr)
CN (1)	CN1264427A (fr)
AT (1)	ATE363533T1 (fr)
AU (4)	AU743257B2 (fr)
BG (1)	BG65242B1 (fr)
BR (1)	BR9808545A (fr)
CA (1)	CA2285746C (fr)
CZ (1)	CZ302262B6 (fr)
DE (1)	DE69837845T3 (fr)
DK (1)	DK0975754T4 (fr)
EA (1)	EA003636B1 (fr)
EE (1)	EE05496B1 (fr)
ES (1)	ES2284203T5 (fr)
HK (1)	HK1022330A1 (fr)
HU (1)	HU230547B1 (fr)
ID (1)	ID23855A (fr)
IL (1)	IL132304A0 (fr)
NO (1)	NO325175B1 (fr)
NZ (1)	NZ500253A (fr)
PL (1)	PL190092B1 (fr)
RO (1)	RO128635A2 (fr)
SI (1)	SI0975754T2 (fr)
SK (1)	SK288559B6 (fr)
TR (1)	TR199902512T2 (fr)
TW (1)	TW589376B (fr)
WO (1)	WO1998046751A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL117175A (en)	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
PT1114864E (pt) *	1996-12-13	2008-10-08	Schering Corp	Antigénios de superfície de células de mamífero, reagentes relacionados
US6271349B1 (en)	1996-12-23	2001-08-07	Immunex Corporation	Receptor activator of NF-κB
DE69738841D1 (de)	1996-12-23	2008-08-28	Immunex Corp	Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
KR100496063B1 (ko)	1997-04-15	2005-06-21	산쿄 가부시키가이샤	신규단백질 및 그 제조방법
AU2008200700C1 (en) *	1997-04-15	2013-04-04	Daiichi Sankyo Co., Ltd	Novel Protein and Process for Producing The Same
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
DK0975754T4 (en)	1997-04-16	2016-03-21	Amgen Inc	Osteoprotegerin binding proteins and their receptors
EP2009025B1 (fr)	1998-05-14	2011-07-27	Immunex Corporation	Procédé d'inhibition de l'activité des ostéoclastes
US20020106728A1 (en) *	2000-06-20	2002-08-08	Genentech, Inc.	NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
DK1114166T3 (da) *	1998-09-15	2005-08-01	Pharmexa As	Fremgangsmåde til nedregulering af osteoprotegerinligandaktivitet
AU754971B2 (en)	1998-09-15	2002-11-28	Pharmexa A/S	Method for down-regulating osteoprotegerin ligand activity
SI2319928T1 (sl)	1998-10-23	2013-08-30	Kirin-Amgen, Inc.	Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost
EP2339003A3 (fr)	1999-06-28	2011-10-19	Genentech, Inc.	Polypeptides variants substitutionnels du ligand Apo-2
EE05673B1 (et)	1999-08-17	2013-08-15	Biogen, Inc.	BAFF-retseptor (BCMA), immunoregulatoorne agens
AU7615600A (en) *	1999-09-27	2001-04-30	Eli Lilly And Company	Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) *	1999-09-29	1999-10-21	University Of Western Australia, The	Bone cell factor
DE60028830T2 (de)	2000-02-16	2007-01-18	Genentech, Inc., South San Francisco	Anti-april antikörper und hybridomazellen
US20030103978A1 (en)	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
MXPA02008144A (es) *	2000-02-23	2002-11-29	Amgen Inc	Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
US6600018B1 (en)	2000-04-10	2003-07-29	The United States Of America As Represented By The Department Of Health And Human Services	Secreted frizzled related protein, sFRP, fragments and methods of use thereof
CN101289511A (zh)	2000-04-11	2008-10-22	杰南技术公司	多价抗体及其应用
ATE415978T1 (de)	2000-07-27	2008-12-15	Genentech Inc	Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
AU2001286586A1 (en) *	2000-08-18	2002-03-04	University Of Massachusetts Medical Center	Trance regulation of chondrocyte differentiation
US6884598B2 (en)	2000-09-22	2005-04-26	Immunex Corporation	Screening assays for agonists and antagonists of receptor activator of NF-κB
PT1387854E (pt)	2001-01-10	2012-06-26	Us Dept Health	Sfrp e motivos de peptídeos que interagem com a sfrp e respectivos métodos de utilização
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
JP4212470B2 (ja) *	2001-06-26	2009-01-21	アムジェンフレモントインク．	Ｏｐｇｌへの抗体
PT1409544E (pt)	2001-07-03	2009-09-16	Genentech Inc	Anticorpos de dr4 humanos e suas utilizações
JP2005508162A (ja)	2001-10-02	2005-03-31	ジェネンテック・インコーポレーテッド	Ａｐｏ−２リガンド変異体とその使用法
EP2322165A1 (fr)	2001-11-13	2011-05-18	Genentech, Inc.	Compositions à base de Apo2 ligand/TRAIL
US7842668B1 (en)	2001-11-13	2010-11-30	Genentech, Inc.	Apo-2 ligand/trail formulations
US7741285B2 (en)	2001-11-13	2010-06-22	Genentech, Inc.	APO-2 ligand/trail formulations
JP4761710B2 (ja)	2002-04-05	2011-08-31	アムジェンインコーポレイテッド	選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
AU2011265413B2 (en) *	2002-04-05	2014-04-10	Amgen Inc.	Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors
EP1556076A4 (fr)	2002-06-24	2009-07-08	Genentech Inc	Variants du ligand apo-2/trail et utilisations de ceux-ci
JP2006521084A (ja)	2002-12-10	2006-09-21	シェーリング−プラウ・リミテッド	イヌｒａｎｋｌならびにイヌｒａｎｋｌを調製および使用するための方法
EP1773400A2 (fr)	2004-07-08	2007-04-18	Amgen Inc.	Peptides therapeutiques
AU2005271249A1 (en)	2004-08-06	2006-02-16	Genentech, Inc.	Assays and methods using biomarkers
CN101035912A (zh)	2004-08-06	2007-09-12	健泰科生物技术公司	使用生物标志的测定法和方法
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
US8029783B2 (en)	2005-02-02	2011-10-04	Genentech, Inc.	DR5 antibodies and articles of manufacture containing same
ZA200800974B (en)	2005-08-16	2009-11-25	Genentech Inc	Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
PE20070684A1 (es)	2005-11-14	2007-08-06	Amgen Inc	MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
JP6088723B2 (ja)	2005-11-23	2017-03-01	ジェネンテック，インコーポレイテッド	Ｂ細胞アッセイに関する組成物及び方法。
JO3324B1 (ar)	2006-04-21	2019-03-13	Amgen Inc	مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
WO2008080112A2 (fr) *	2006-12-22	2008-07-03	The Regents Of The University Of California	Nouvelle molécule de fusion basée sur un nouveau variant taa
CA2840407A1 (fr)	2007-05-22	2008-12-18	Amgen Inc.	Compositions et procedes pour produire des proteines de fusion bioactives
JP2008307007A (ja)	2007-06-15	2008-12-25	Bayer Schering Pharma Ag	出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US8637257B2 (en)	2007-06-20	2014-01-28	Galapagos Nv	Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
JP5346925B2 (ja) *	2008-05-02	2013-11-20	国立大学法人京都大学	核初期化方法
WO2010062904A2 (fr)	2008-11-25	2010-06-03	Biogen Idec Ma Inc.	Utilisation d'antagonistes dr6 et p75 pour favoriser la survie de cellules du systeme nerveux
EP2433644A1 (fr)	2010-09-22	2012-03-28	IMBA-Institut für Molekulare Biotechnologie GmbH	Traitement du cancer du sein
EP2434285A1 (fr)	2010-09-22	2012-03-28	IMBA-Institut für Molekulare Biotechnologie GmbH	Diagnostic du cancer du sein
US20150025077A1 (en)	2012-02-29	2015-01-22	Coyote Pharmaceuticals, Inc.	Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
US9119808B1 (en)	2012-10-08	2015-09-01	Coyote Pharmaceuticals, Inc.	Treating neurodegenerative diseases with GGA or a derivative thereof
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
WO2014144817A2 (fr)	2013-03-15	2014-09-18	Amgen Inc.	Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt
JP6668241B2 (ja)	2013-09-05	2020-03-18	アムジエン・インコーポレーテツド	予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
WO2015175861A1 (fr)	2014-05-16	2015-11-19	Amgen Inc.	Dosage pour la détection de populations de cellules th1 et th2
US11680101B2 (en)	2017-01-27	2023-06-20	Kymab Limited	Anti-OPG antibodies
CA3056011A1 (fr)	2017-03-14	2018-09-20	Amgen Inc.	Controle des glycoformes afucosylees totales d'anticorps produits en culture cellulaire
EP3713581A1 (fr)	2017-11-22	2020-09-30	Inbiomotion S.L.	Traitement thérapeutique du cancer du sein basé sur le c-maf
SG11202009216YA (en)	2018-03-26	2020-10-29	Amgen Inc	Total afucosylated glycoforms of antibodies produced in cell culture
KR20220069982A (ko)	2019-09-26	2022-05-27	암젠 인크	항체 조성물의 생산 방법
CN113621060B (zh) *	2020-05-07	2023-07-04	浙江瑞硕生物技术有限公司	一种opg抗体对及其应用
WO2021247892A1 (fr)	2020-06-04	2021-12-09	Amgen Inc.	Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique
JP2023548767A (ja)	2020-10-15	2023-11-21	アムジエン・インコーポレーテツド	抗体製造方法における相対不対グリカン
AR126089A1 (es)	2021-06-07	2023-09-13	Amgen Inc	Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
WO2023059607A1 (fr)	2021-10-05	2023-04-13	Amgen Inc.	Liaison de récepteur fc-gamma et teneur en glycane
WO2023215725A1 (fr)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions et méthodes pour l'immunothérapie cellulaire

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4710457A (en)	1983-06-29	1987-12-01	Sloan-Kettering Institute For Cancer Research	Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en)	1983-08-10	1987-12-01	Amgen, Inc.	DNA plasmids
US4959314A (en)	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US6410516B1 (en) *	1986-01-09	2002-06-25	President & Fellows Of Harvard College	Nuclear factors associated with transcriptional regulation
US5846534A (en)	1988-02-12	1998-12-08	British Technology Group Limited	Antibodies to the antigen campath-1
AU651421B2 (en)	1990-11-30	1994-07-21	Celtrix Pharmaceuticals, Inc.	Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair
US5118667A (en)	1991-05-03	1992-06-02	Celtrix Pharmaceuticals, Inc.	Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (fr)	1991-05-13	1992-11-14	Masahiko Sato	Methode d'inhibition de la resorption osseuse
MX9204303A (es)	1991-07-23	1993-11-01	Rhone Poulenc Rorer Int	Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en)	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5961974A (en) *	1991-10-25	1999-10-05	Immunex Corporation	Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5447851B1 (en)	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0639079B1 (fr)	1992-04-30	2000-01-12	Amgen Inc.	Methodes de traitement des maladies induites par l'interleukine-1 et le facteur de necrose tumorale
US5585479A (en)	1992-07-24	1996-12-17	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en)	1993-03-12	1996-11-26	Tam; Cherk S.	Method of increasing bone growth
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
JPH09502614A (ja)	1993-09-14	1997-03-18	メルクエンドカンパニーインコーポレーテッド	新規ヒト蛋白質チロシンホスファターゼをコードするｃＤＮＡ
US6268212B1 (en)	1993-10-18	2001-07-31	Amgen Inc.	Tissue specific transgene expression
US5641747A (en)	1994-07-25	1997-06-24	Temple University-Of The Commonwealth System Of Higher Education	Treatment of osteopetrotic diseases
EP0792278B1 (fr) *	1994-11-07	2007-06-13	Human Genome Sciences, Inc.	Polypeptide gamma appartenant a la famille des facteurs de necrose tumorale (fnt)
EP0727211A1 (fr)	1995-02-10	1996-08-21	Smithkline Beecham Corporation	Emploi de composés spécifiques src SH2 dans le traitement de maladies de résorption osseuse
IL117175A (en)	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
US20030166097A1 (en) *	1995-03-15	2003-09-04	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
US7094564B1 (en)	1995-03-15	2006-08-22	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
WO1996028546A1 (fr)	1995-03-15	1996-09-19	Human Genome Sciences, Inc.	Recepteur humain du facteur de necrose tumorale
AU5985996A (en)	1995-06-07	1997-01-15	Osteosa Inc.	Osteoclast growth regulatory factor
AU6090896A (en)	1995-06-07	1997-01-15	Osteosa Inc.	Osteoclast growth regulatory factor
US5843901A (en)	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
DK0835305T3 (da) *	1995-06-29	2006-02-13	Immunex Corp	Cytokin som inducerer apoptose
US6369027B1 (en)	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin
US6613544B1 (en)	1995-12-22	2003-09-02	Amgen Inc.	Osteoprotegerin
US6046048A (en)	1996-01-09	2000-04-04	Genetech, Inc.	Apo-2 ligand
US5981220A (en) *	1996-03-27	1999-11-09	Human Genome Sciences, Inc.	Epidermal differentiation factor
TW555765B (en) *	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JPH1057071A (ja)	1996-08-19	1998-03-03	Snow Brand Milk Prod Co Ltd	新規ｄｎａ及びそれを用いた蛋白質の製造方法
PT1114864E (pt)	1996-12-13	2008-10-08	Schering Corp	Antigénios de superfície de células de mamífero, reagentes relacionados
FR2757507B1 (fr)	1996-12-20	1999-01-29	Inst Francais Du Petrole	Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
AU5901598A (en)	1996-12-20	1998-07-17	Board Of Regents, The University Of Texas System	Compositions and methods of use for osteoclast inhibitory factors
US6271349B1 (en)	1996-12-23	2001-08-07	Immunex Corporation	Receptor activator of NF-κB
DE69738841D1 (de)	1996-12-23	2008-08-28	Immunex Corp	Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
KR100496063B1 (ko) *	1997-04-15	2005-06-21	산쿄 가부시키가이샤	신규단백질 및 그 제조방법
DK0975754T4 (en)	1997-04-16	2016-03-21	Amgen Inc	Osteoprotegerin binding proteins and their receptors
US5843678A (en) *	1997-04-16	1998-12-01	Amgen Inc.	Osteoprotegerin binding proteins
US6316408B1 (en) *	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
CA2229449A1 (fr) *	1997-04-25	1998-10-25	Takeda Chemical Industries, Ltd.	Proteine receptrice nouvelle et son utilisation
AU7469998A (en)	1997-05-01	1998-11-24	Amgen, Inc.	Chimeric opg polypeptides
WO1998054201A1 (fr)	1997-05-29	1998-12-03	Human Genome Sciences, Inc.	Proteine 8 apparentee au recepteur du facteur de necrose tumorale humain
US6087555A (en)	1997-10-15	2000-07-11	Amgen Inc.	Mice lacking expression of osteoprotegerin
US6790823B1 (en)	1998-04-23	2004-09-14	Amgen Inc.	Compositions and methods for the prevention and treatment of cardiovascular diseases
EP2009025B1 (fr) *	1998-05-14	2011-07-27	Immunex Corporation	Procédé d'inhibition de l'activité des ostéoclastes
AU754971B2 (en) *	1998-09-15	2002-11-28	Pharmexa A/S	Method for down-regulating osteoprotegerin ligand activity
AU6078500A (en)	1999-07-09	2001-01-30	Amgen, Inc.	Combination therapy for conditions leading to bone loss
EP1140136B1 (fr)	1999-09-03	2007-05-16	Amgen Inc.	Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
US20030144187A1 (en)	1999-09-03	2003-07-31	Colin R. Dunstan	Opg fusion protein compositions and methods
US20030103978A1 (en) *	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
MXPA02008144A (es)	2000-02-23	2002-11-29	Amgen Inc	Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
AU2001286586A1 (en)	2000-08-18	2002-03-04	University Of Massachusetts Medical Center	Trance regulation of chondrocyte differentiation
US6884598B2 (en) *	2000-09-22	2005-04-26	Immunex Corporation	Screening assays for agonists and antagonists of receptor activator of NF-κB
ES2212930T1 (es)	2001-05-17	2004-08-16	Immunex Corporation	Uso terapeutico de antagonistas de rank.
CA2449658A1 (fr) *	2001-06-06	2002-12-12	Immunex Corporation	Utilisation d'antagonistes rank dans le traitement du cancer
JP4212470B2 (ja)	2001-06-26	2009-01-21	アムジェンフレモントインク．	Ｏｐｇｌへの抗体
US6753755B2 (en) *	2001-06-28	2004-06-22	Safer Home, Inc.	Electrical safety connector fuse
US7084257B2 (en) *	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6592001B2 (en) *	2001-12-18	2003-07-15	Kimberly-Clark Worldwide	Dispenser for sheet material containing a dispensing port incrementally variable within a range
JP4761710B2 (ja)	2002-04-05	2011-08-31	アムジェンインコーポレイテッド	選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
US7706431B2 (en) *	2005-06-30	2010-04-27	Nokia Corporation	System and method for providing optimized receiver architectures for combined pilot and data signal tracking

1998
- 1998-04-15 DK DK98918244.9T patent/DK0975754T4/en active
- 1998-04-15 PL PL98336311A patent/PL190092B1/pl unknown
- 1998-04-15 JP JP54425798A patent/JP2001526532A/ja not_active Withdrawn
- 1998-04-15 ES ES98918244.9T patent/ES2284203T5/es not_active Expired - Lifetime
- 1998-04-15 AT AT98918244T patent/ATE363533T1/de active
- 1998-04-15 AU AU71205/98A patent/AU743257B2/en not_active Ceased
- 1998-04-15 EA EA199900939A patent/EA003636B1/ru not_active IP Right Cessation
- 1998-04-15 EE EEP199900611A patent/EE05496B1/xx unknown
- 1998-04-15 SI SI9830889T patent/SI0975754T2/sl unknown
- 1998-04-15 HU HU0001400A patent/HU230547B1/hu unknown
- 1998-04-15 EP EP06015956A patent/EP1717315A3/fr not_active Withdrawn
- 1998-04-15 TR TR1999/02512T patent/TR199902512T2/xx unknown
- 1998-04-15 CZ CZ0359899A patent/CZ302262B6/cs not_active IP Right Cessation
- 1998-04-15 CA CA2285746A patent/CA2285746C/fr not_active Expired - Lifetime
- 1998-04-15 IL IL13230498A patent/IL132304A0/xx unknown
- 1998-04-15 BR BR9808545-0A patent/BR9808545A/pt not_active Application Discontinuation
- 1998-04-15 RO ROA201200577A patent/RO128635A2/ro unknown
- 1998-04-15 ID IDW991225A patent/ID23855A/id unknown
- 1998-04-15 DE DE69837845.8T patent/DE69837845T3/de not_active Expired - Lifetime
- 1998-04-15 CN CN98806073A patent/CN1264427A/zh active Pending
- 1998-04-15 NZ NZ500253A patent/NZ500253A/xx not_active IP Right Cessation
- 1998-04-15 WO PCT/US1998/007584 patent/WO1998046751A1/fr active IP Right Grant
- 1998-04-15 SK SK1419-99A patent/SK288559B6/sk active Protection Beyond IP Right Term
- 1998-04-15 EP EP98918244.9A patent/EP0975754B2/fr not_active Expired - Lifetime
- 1998-04-16 TW TW087105837A patent/TW589376B/zh not_active IP Right Cessation
1999
- 1999-10-15 NO NO19995044A patent/NO325175B1/no not_active IP Right Cessation
- 1999-10-21 BG BG103824A patent/BG65242B1/bg unknown
2000
- 2000-02-25 HK HK00101154A patent/HK1022330A1/xx not_active IP Right Cessation
2001
- 2001-11-30 AU AU95234/01A patent/AU779461C/en not_active Expired
2005
- 2005-04-27 AU AU2005201799A patent/AU2005201799B2/en not_active Expired
2006
- 2006-01-19 US US11/336,067 patent/US7923008B2/en not_active Expired - Fee Related
2007
- 2007-09-04 JP JP2007228804A patent/JP5001758B2/ja not_active Expired - Lifetime
2008
- 2008-06-05 AU AU2008202516A patent/AU2008202516A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HU230547B1 (hu)	2016-11-28
DK0975754T3 (da)	2007-10-01
BG65242B1 (bg)	2007-09-28
CA2285746A1 (fr)	1998-10-22
EP0975754B2 (fr)	2016-01-06
EA003636B1 (ru)	2003-08-28
CZ302262B6 (cs)	2011-01-19
HUP0001400A3 (en)	2001-12-28
AU2008202516A1 (en)	2008-06-26
SK288559B6 (sk)	2018-05-02
NO325175B1 (no)	2008-02-11
DE69837845T3 (de)	2016-06-23
US7923008B2 (en)	2011-04-12
AU779461C (en)	2005-10-13
CA2285746C (fr)	2010-09-28
AU2005201799A1 (en)	2005-05-26
EA199900939A1 (ru)	2000-08-28
BG103824A (en)	2000-05-31
DE69837845D1 (de)	2007-07-12
JP2001526532A (ja)	2001-12-18
US20060246064A1 (en)	2006-11-02
SI0975754T1 (sl)	2007-10-31
EP1717315A3 (fr)	2007-06-20
WO1998046751A1 (fr)	1998-10-22
PL336311A1 (en)	2000-06-19
BR9808545A (pt)	2000-05-23
HUP0001400A2 (en)	2000-07-28
SK141999A3 (en)	2000-05-16
NO995044L (no)	1999-12-15
SI0975754T2 (sl)	2016-04-29
EP0975754B1 (fr)	2007-05-30
ES2284203T5 (es)	2016-03-11
JP5001758B2 (ja)	2012-08-15
AU7120598A (en)	1998-11-11
DK0975754T4 (en)	2016-03-21
NO995044D0 (no)	1999-10-15
EP0975754A1 (fr)	2000-02-02
TR199902512T2 (xx)	2000-06-21
DE69837845T2 (de)	2008-01-31
ES2284203T3 (es)	2007-11-01
ID23855A (id)	2000-05-25
RO128635A2 (ro)	2013-07-30
JP2008054682A (ja)	2008-03-13
TW589376B (en)	2004-06-01
CZ359899A3 (cs)	2000-02-16
NZ500253A (en)	2002-09-27
HK1022330A1 (en)	2000-08-04
AU2005201799B2 (en)	2008-06-12
AU743257B2 (en)	2002-01-24
CN1264427A (zh)	2000-08-23
EE9900611A (et)	2000-08-15
ATE363533T1 (de)	2007-06-15
PL190092B1 (pl)	2005-10-31
AU9523401A (en)	2002-01-24
EE05496B1 (et)	2011-12-15
EP1717315A2 (fr)	2006-11-02
AU779461B2 (en)	2005-01-27

Publication	Publication Date	Title
AU779461C (en)	2005-10-13	Osteoprotegerin binding proteins and receptors
Kasugai et al.	1991	Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter
HU9600692D0 (en)	1996-05-28	Human metabotropic glutamate receptor subtypes (hmr4, hmr6, hmr7) and related dna compounds
EP2325316B8 (fr)	2017-04-19	Protéine réceptrice d'hémopoïétine, NR10
WO1995030003A3 (fr)	1995-12-14	Recepteurs de surface de cellule morphogenes specifiques d'une proteine et leurs usages
BR9814335A (pt)	2000-10-10	Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr)
NZ508381A (en)	2002-09-27	Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
EA199700143A1 (ru)	1997-12-30	Способ и композиция ждя липидизации гидрофильных молекул
EP0679093A1 (fr)	1995-11-02	Procede d'apport d'agents a des cellules cibles.
ES2009590A6 (es)	1989-10-01	Metodo de preparacion de proteina de cadena pesada del factor tisular humano.
WO1995009872B1 (fr)	1995-05-04	Adn codant pour un recepteur ip de prostaglandine
DE69738370D1 (de)	2008-01-24	Modulatoren des tnf-rezeptor-assoziierten faktors, deren herstellung und verwendungen
EP0861896A3 (fr)	1999-10-20	Kinase humaine regulé par le volume de cellule (h-sgk)
NZ333203A (en)	2000-07-28	Tumour antigen proteins, genes thereof, and tumour antigen peptides
WO1997007135A3 (fr)	1997-05-22	Liaison de la proteine oestrogene 1 (op-1) et de ses analogues avec le recepteur alk-1 de surface de cellule et ses analogues
BR0013043A (pt)	2002-04-30	Proteìna isolada, anticorpo isolado, composição, método de regulação de reação imunológica em animais, método de tratamento de câncer em animais, molécula de ácido nucleico isolado, molécula de ácido nucleico recombinante, célula recombinante e vìrus recombinante
CA2312274A1 (fr)	2000-04-13	Adn isole codant pour un recepteur h3 d'histamine humain
WO1999063094A3 (fr)	2000-04-13	Sequences nucleotidiques et proteiques gpr1 et methodes y relatives
WO1999019480A3 (fr)	1999-06-24	Proteines receptrices humaines et reactifs et methodes associes
GEP20002244B (en)	2000-09-25	Osteoprotegerin
MX9701267A (es)	1997-11-29	Receptor de glutamato.
HUP0001774A3 (en)	2005-11-28	Fragments of leptin (ob protein)